Hideaki Matsuoka
Corporate Officer/Principal at Astellas Venture Management LLC
Network origin in Hideaki Matsuoka first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.
2
| Subsidiary | Investment Managers | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Hideaki Matsuoka via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| Tokyo University of Science | College/University | Undergraduate Degree | |
| Yamanouchi Pharma America, Inc. | Director/Board Member | ||
Astellas Pharma US, Inc.
 Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Pharmaceuticals: Major | Director/Board Member | |
| Kyoto University | College/University | Graduate Degree | |
| University of Massachusetts | College/University | Masters Business Admin | |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
| ASTELLAS PHARMA INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| United States | 6 |
| Japan | 4 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Operational
| Director/Board Member | 4 |
| Private Equity Investor | 2 |
| Undergraduate Degree | 2 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Satoshi Konagai | 6 |
| Tadayoshi Hirata | 4 |
- Stock Market
- Insiders
- Hideaki Matsuoka
- Company connections
